
Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBAAbbVie is a biopharmaceutical company that develops medicines in immunology, oncology, and neuroscience, and also works in eye care and aesthetics.
AbbVie became an independent company in January 2013, when Abbott separated its research based pharmaceuticals business. It is headquartered in North Chicago, Illinois. The company discovers, develops, and sells prescription medicines used mainly by specialists, and it reaches patients through health systems, pharmacies, and payers. Its pipeline spans small molecules, biologics, and antibody drug conjugates, a class of cancer therapy that attaches a drug to an antibody aimed at tumor cells. Alongside its medicines, AbbVie has eye care and medical aesthetics businesses.
Leadership as of 14 November 2026.
Chairman of the Board and Chief Executive Officer

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBARelated companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: